Ionis Slashes 2026 Tryngolza Guidance, Shares Sink Toward 52-Week Low
IONS is trading near its 52-week low of $27.75 (3.3% above the low) on elevated volume (1.9× avg).
Summary
Ionis cut its 2026 TRYNGOLZA sales guidance to about $100 million, disclosed alongside Q3 revenue of $243 million and a $0.66 per-share loss. The stock is falling hard and now trades near its 52-week low of $27.75, down from a high of $86.74. The problem is concentrated: the 10-Q shows DAWNZERA offsetting a sharp TRYNGOLZA decline, so the launch that was supposed to anchor the commercial story is undershooting. This lands just weeks after CHMP recommended EU approval of TRYNGOLZA in severe hypertriglyceridemia, which makes the US demand shortfall the more glaring issue. The rest of the pipeline has been delivering — zilganersen approved in September, positive Phase 3 data for ulefnersen and sefaxersen — but those are partner-driven or early-revenue assets, and pelacarsen's Phase 3 failure already removed one royalty stream.
At the time of this announcement, IONS was trading at $28.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $27.75 to $86.74. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.